CAR T cells and systemic lupus erythematosus SLE (Marko Radic)

Impulse at the Interdisciplinary Discussion "Expanding the Scope
of CAR T Cell Therapy", 08. - 09. April 2024, Halle (Saale)
The onset of Chimeric Antigen Receptor (CAR) T cell therapy marks a revolutionary development in the field of immunotherapy, achieving notable success since its approval in 2017 for treating B cell malignan-cies. Designing a patient's own T cells to specifically identify and eradicate tumor cells has successfully treated individuals with previously incurable hematologic cancers.
While CAR T cells are currently predominantly utilized in anti-tumor therapy, their initial conceptualization aimed at a broader objective of targeting membrane antigens, opening the door to numerous potential applications. Subsequent studies have explored the application of CAR T cells in non-malignant pathologies, encompassing autoimmune diseases, infectious diseases, and more recently, conditions such as cardiac fibrosis and cellular senescence.
Within this interdisciplinary discussion, key findings and implications of CAR-based therapies for non-malignant conditions are presented.
More on the event: www.leopoldina.org/en/events/...